ES2044941T5 - Estabilizador de hormonas promotoras del crecimiento. - Google Patents

Estabilizador de hormonas promotoras del crecimiento.

Info

Publication number
ES2044941T5
ES2044941T5 ES87307406T ES87307406T ES2044941T5 ES 2044941 T5 ES2044941 T5 ES 2044941T5 ES 87307406 T ES87307406 T ES 87307406T ES 87307406 T ES87307406 T ES 87307406T ES 2044941 T5 ES2044941 T5 ES 2044941T5
Authority
ES
Spain
Prior art keywords
growth promoting
stabilizer
amino acids
promoting hormones
hormones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87307406T
Other languages
English (en)
Other versions
ES2044941T3 (es
ES2044941T4 (es
Inventor
Edwin J Hamilton Jr
Bruce D Burleigh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8198005&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2044941(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of ES2044941T3 publication Critical patent/ES2044941T3/es
Application granted granted Critical
Publication of ES2044941T4 publication Critical patent/ES2044941T4/es
Publication of ES2044941T5 publication Critical patent/ES2044941T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Liquid Deposition Of Substances Of Which Semiconductor Devices Are Composed (AREA)
  • Medicinal Preparation (AREA)
  • Chemical Vapour Deposition (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

LAS HORMONAS DEL CRECIMIENTO PUEDEN SER MEZCLADAS CON VARIOS ESTABILIZADORES PARA MANTENER LA FORMACION DISMINUIDA DE INSOLUBLES Y LA CONSERVACION DE LA BIOACTIVIDAD SOLUBLE DE LA HORMONA QUE FOMENTA EL CRECIMIENTO EN AMBIENTES ACUOSOS. EJEMPLO DE TALES ESTABILIZADORES INCLUYEN CIERTOS POLIOLES, AMINOACIDOS, POLIMEROS DE AMINOACIDOS QUE TIENEN GRUPOS LATERALES CARGADOS DE PH FISIOLOGICOS Y SALES COLINAS.
ES87307406T 1987-08-21 1987-08-21 Estabilizador de hormonas promotoras del crecimiento. Expired - Lifetime ES2044941T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87307406A EP0303746B2 (en) 1987-08-21 1987-08-21 Stabilization of growth promoting hormones

Publications (3)

Publication Number Publication Date
ES2044941T3 ES2044941T3 (es) 1994-01-16
ES2044941T4 ES2044941T4 (es) 1996-07-16
ES2044941T5 true ES2044941T5 (es) 1999-02-16

Family

ID=8198005

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87307406T Expired - Lifetime ES2044941T5 (es) 1987-08-21 1987-08-21 Estabilizador de hormonas promotoras del crecimiento.

Country Status (5)

Country Link
EP (1) EP0303746B2 (es)
AT (1) ATE82506T1 (es)
DE (1) DE3782737T3 (es)
ES (1) ES2044941T5 (es)
HU (1) HU202117B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5122512A (en) * 1988-09-12 1992-06-16 Pitman-Moore, Inc. Swine growth promoting composition
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
SE9002731D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product comprising growth factor
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
CA2133737A1 (en) * 1992-04-07 1993-10-14 James E. Seely Lyophilized somatotropin formulations
MD1699F2 (ro) * 1992-07-31 2001-07-31 Genentech, Inc. Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei
ATE220327T1 (de) 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
JP3698721B2 (ja) * 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
DK0804223T3 (da) * 1994-06-17 2000-01-24 Applied Research Systems Farmaceutiske præparater indeholdende hGH
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
AUPN801296A0 (en) 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
ZA9711731B (en) 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
CN1245216C (zh) 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
KR20080011353A (ko) * 2000-02-24 2008-02-01 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
AU2001271491A1 (en) 2000-06-26 2002-01-08 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
WO2002011695A2 (en) 2000-08-07 2002-02-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CA2512052C (en) 2002-12-31 2016-06-21 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
DK1599222T3 (da) 2003-01-08 2009-04-27 Novartis Vaccines & Diagnostic Stabiliserede vandige pr parater omfattende v vsfaktorvej-inhibitor (TFPI) eller v vsfaktorvej-inhibitorvariant
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
PT2049148T (pt) * 2006-07-06 2016-12-30 Daewoong Co Ltd Formulação líquida estável da hormona do crescimento humana
BRPI1006519A2 (pt) 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
RS59830B1 (sr) 2010-03-01 2020-02-28 Bayer Healthcare Llc Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
GB2499480A (en) * 2010-03-31 2013-08-21 Stabilitech Ltd Method for preserving alum adjuvants and alum-adjuvanted vaccines
US20130089912A1 (en) * 2011-10-06 2013-04-11 Gloria Elliott Methods and compositions for the stabilization of biologic material
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
JP5487276B2 (ja) * 2012-11-12 2014-05-07 デウン カンパニー，リミテッド ヒト成長ホルモンを含有する安定した液状製剤
DE102020125874A1 (de) * 2020-10-02 2022-04-07 Dr. Kurt Wolff Gmbh & Co. Kg Zusammensetzung zur Behandlung von Haaren und der Haut

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0193917A3 (en) * 1985-03-06 1987-09-23 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration
US4670249A (en) * 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions

Also Published As

Publication number Publication date
ES2044941T3 (es) 1994-01-16
EP0303746B1 (en) 1992-11-19
ATE82506T1 (de) 1992-12-15
EP0303746A1 (en) 1989-02-22
DE3782737T2 (de) 1993-04-01
EP0303746B2 (en) 1998-12-02
HU202117B (en) 1991-02-28
DE3782737T3 (de) 1999-05-20
ES2044941T4 (es) 1996-07-16
HUT44706A (en) 1988-04-28
DE3782737D1 (de) 1992-12-24

Similar Documents

Publication Publication Date Title
ES2044941T4 (es) Estabilizacion de hormonas promotoras del crecimiento.
DE3583518D1 (de) Produktion von eiern.
AU6020186A (en) Process for production of dry bioactive recombinant growth hormones
SE8505048L (sv) Nutritionsemulsion med syretransporterande egenskaper
EP0203649A3 (en) Pharmaceutic composition based on diphoshonates for the treatment of the arthrosis
FI882605A0 (fi) Menetelmä, jonka avulla voidaan valmistaa suuren spesifisen tilavuusaktiivisuuden omaavaa liuosta proteiinista, jolla on kudosplasminogeeniaktivaattori(t-PA)-aktiivisuutta
GR3003517T3 (es)
ATE114470T1 (de) Behandlung von intraocularem druck mit einer synergistischen kombination zur ophthalmischen verwendung.
DK481589D0 (da) Lipidmetabolismefremmende middel
FI875295A0 (fi) Menetelmä hirudiinivariantin valmistamiseksi
NO178325C (no) Fremgangsmåte for fremstilling av et t-PA injeksjonspreparat
FI98891B (fi) Menetelmä vesiliuoksen proteiinipitoisuuden lisäämiseksi
ATE53491T1 (de) Niedrig osmotisches hypokalorisches waessriges praeparat fuer die infusion.
KR880008812A (ko) 항균성 동결건조 제제
DE3167839D1 (en) Method for preparing n-(4-(((2,4-diamino-6-pteridinyl)-methyl)methylamino)benzoyl)glutamic acid
ATE18410T1 (de) Kristallines human-leukocyten-interferon.
EP0260092A3 (en) Optically active beta-amino acid derivatives and their salts, and processes for producing the same
BG50927A3 (bg) Метод за получаване на стабилизирани стимулиращи растежа хормони
ZA885502B (en) Preparation for preventing or combating complications in diabetes
CS699187A2 (en) Stabilized means for farming animals' growth stimulation

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 303746

Country of ref document: ES

FG2A Definitive protection

Ref document number: 0303746

Country of ref document: ES